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Alcohol use disorders (AUD) are one of the most common and devastating forms of 
drug addiction in Australia. However, current treatments are severely lacking in 
effective pharmacological options. In recent years, the trace-amine associated 
receptor 1 (TAAR1) has been identified as a potential target for new 
pharmacological interventions in drug addiction, showing effectiveness in reducing 
cocaine- and methamphetamine-addiction related behaviours in animal models. 
However, the effects of TAAR1 activation on alcohol addiction have not been 
addressed. This study aimed to examine the potential therapeutic effects of TAAR1 
activation with the partial agonist, RO5263397, on alcohol self-administration and 
locomotor sensitisation behaviours in a rodent model of alcohol addiction. The data 
showed that TAAR1-activation resulted in a significant decrease of ethanol 
consumption in g/kg in the first hour of the self-administration test, and a significant 
decrease in locomotor activity. However, there was no effect on ethanol 
consumption in mL or preference. Furthermore, TAAR1 activation was also found to 
significantly reduce sucrose and water consumption (mL) which was unexpected. 
These findings provide an important first look at the effects of TAAR1 activation on 
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Therapeutic-like Effects of Trace Amine Associated Receptor 1 (TAAR1) 
Activation in Models of Alcohol Abuse 
Alcohol Use Disorder in Australia 
Alcohol use disorder (AUD) is a harmful pattern of alcohol use characterised 
by a number of symptoms, including an excessive and uncontrollable intake of 
alcohol despite awareness of its negative effects (American Psychiatric Association, 
2013). It is graded on a spectrum of severity, which is determined by the number of 
symptoms present: 2-3 is mild, 4-5 is moderate, and 6 or more is severe and 
considered to meet the criteria for alcohol abuse (American Psychiatric Association, 
2013; Campbell, Lawrence, & Perry, 2018; Freyer, Morley, & Haber, 2016). 
Alcohol addiction is one of the most persistent and harmful forms of substance 
addiction, being one of the three biggest contributors to global disease burden 
(Gowing et al., 2015; World Health Organisation, 2018). An estimated 50% of all 
alcohol-related harms occur in patients diagnosed with AUD, highlighting the 
severity of the problem, and making the development of more effective treatments a 
priority (Gowing et al., 2015; World Health Organisation, 2018). 
AUDs are highly prevalent in Australia (Teeson et al., 2010). The 2007 
National Survey of Mental Health and Wellbeing (NSMHW) found that 22.1% of 
the population experienced some form of AUD over their lifetime (Teeson et al., 
2010) with AUDs being significantly more common in males and young adults, a 
finding reflected in international patterns (World Health Organisation, 2018). 
Lifetime prevalence rates for AUDs in Australia widely vary, with estimates ranging 
from 4.5% to 17.8%, with it being most common among unmarried, English-
speaking males (Teeson et al., 2010). The mean age of onset is approximately 20-22 
years, with the hazard rate peaking at 18 (Teeson et al., 2010). Severity of symptoms 
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tend to escalate throughout the mid to late 20’s, which is the age range most people 
without an AUD decrease in problematic alcohol use behaviours (Freyer et al., 
2016).  
Over 200 conditions have been linked to the misuse of alcohol, with 
examples including liver and cardiovascular disease, injuries resulting from road 
accidents, suicide, tuberculosis, and HIV/AIDS (Freyer et al., 2016; World Health 
Organisation, 2018). Within Australia, alcohol addiction contributed 2.6% of total 
disease burden in 2010 (Freyer et al., 2016). What makes alcohol addiction more 
insidious is that these clinical effects can appear to be blunted and therefore harder to 
detect in those who are alcohol-dependent, further compounding the risk of negative 
effects (Freyer et al., 2016). There is evidence that AUD rates are rising in Australia, 
even as general alcohol consumption decreases, as indicated by an increased rate of 
hospital admissions for this disorder and other associated conditions such as liver 
disease (Freyer et al., 2016).  
 
Pharmacological Treatments for Alcohol Use Disorder: The Current State 
Due to these detrimental effects, the low rate of success in treating alcohol 
use disorders is a significant public health concern (Freyer et al., 2016; Revel, 
Hoener, Renau-Piqueras & Canales, 2012; Teesson et al., 2010). There are numerous 
factors behind the low success rate, chief of these being the high rate of comorbidity 
with other substance use disorders, anxiety, and depression, as well as the social 
stigma attached to the disorder (Campbell, Lawrence & Perry, 2018; Freyer et al., 
2016).  AUDs are traditionally treated with a combination of psychosocial therapy 
and pharmacological treatments however the goal of these programs is usually to 
reduce drinking down to a manageable level and to prevent relapse, rather than 
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function as an outright cure (Campbell et al., 2018; Freyer et al., 2016; Revel et al., 
2012). In situations where the disorder is comorbid with other mental illnesses, AUD 
is often prioritised in treatment due to its exacerbating effects on other mental 
illnesses (Freyer et al., 2016; Teeson et al., 2010). In addition to this, numerous 
public health programs have been implemented around the world in order to reduce 
the harmful effects of alcohol consumption through education and spreading 
awareness in an effort to combat some of the social stigma (Campbell et al., 2018; 
World Health Organisation, 2018). However, these have been largely ineffective in 
reducing rates of alcohol misuse (Campbell et al., 2018; World Health Organisation, 
2018), therefore making the development of new and effective treatments a priority. 
In most cases of AUD, the initial withdrawal period after ceasing alcohol 
consumption is often cited as the most difficult aspect of quitting or controlling 
intake in patients. These effects are most severe in heavy alcohol drinkers who 
experience a sudden and substantial decrease in the amount of alcohol they consume 
(Freyer et al., 2016). Symptoms of alcohol withdrawal can be as minor as tremors, 
insomnia, headaches, and anxiety, to as severe as seizures and hallucinations, which 
can require hospitalisation (Freyer et al., 2016). In patients with comorbid disorders, 
withdrawal symptoms are often exacerbated, along with the symptoms of their 
comorbid disorders, which can be a very painful and traumatic experience for the 
patient. It is these severe and complex cases of alcohol abuse that may benefit the 
most from effective and targeted pharmacological treatments (Freyer et al., 2016; 
Lynch et al., 2013). However, there are currently no specific drugs for treating either 
alcohol withdrawal or AUD. Health care professionals and hospitals generally use 
benzodiazepines such as diazepam, as a short-term treatment (Campbell et al., 2018; 
Freyer et al., 2016). However, this is ineffective as an ongoing treatment. For long-
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term cases, there are currently only three medications approved for this use in 
Australia: acamprosate, naltrexone, and disulfiram. Acamprosate and naltrexone 
specifically target the craving symptoms and have been shown to be effective in 
maintaining abstinence and decreasing alcohol intake in relapsed patients (Campbell 
et al., 2018; Freyer et al., 2016; Lynch et al., 2013). However, adherence rates 
remain low and side-effects include diarrhea, fatigue, and nausea (Freyer et al., 
2016). Furthermore, acamprosate cannot be taken by patients who have advanced 
cirrhosis, and/or moderate to severe renal impairment. Disulfiram is different from 
the first two as it is an active deterrent. Upon consuming or being exposed to 
alcohol, disulfiram triggers the accumulation of toxic acetaldehyde, causing feelings 
of nausea (Campbell et al., 2018; Freyer et al., 2016; Lynch et al., 2013). Moreover, 
this drug can have severe side-effects in some patients which can be fatal, therefore 
this medication is not recommended unless taken under close professional 
supervision (Freyer et al., 2016). Finally, all current drugs used to treat alcohol abuse 
are only effective if the patient has already abstained from alcohol use (Campbell et 
al., 2018; Lynch et al., 2013). Therefore, there is a need for medications that can 
target withdrawal symptoms and encourage abstinence when the patient is still 
consuming alcohol. In doing so, other courses of treatment such as psychotherapy 
can be maintained, leading to an overall increase in therapy effectiveness and 
recovery success rates (Revel, Mayer et al., 2012).  
 
The role of the trace amine associated receptor 1 (TAAR1) 
Trace amines (TAs) are a family of endogenous molecules with strong 
similarities to classical monoamines that are now considered a class of 
neurotransmitters in their own right (Pei et al., 2014). They are present in very low, 
EFFECTS OF TAAR1 ACTIVATION ON ALCOHOL ABUSE 
	
13	
trace concentrations in the central nervous system (CNS), several hundred times 
weaker than classical neurotransmitters, hence their name of ‘trace’ amine. They are 
most highly concentrated in the nigrostriatal and mesolimbic dopaminergic pathways 
such as the ventral tegmental area (VTA), substantia nigra and nucleus accumbens 
(Pei, Asif-Malik & Canales, 2016). Until recently, they were classified as false 
neurotransmitters in vertebrates as there was no identified specific receptor for them 
(Pei et al., 2016).  
The trace amine-associated receptor 1 (TAAR1), a G-protein coupled 
receptor expressed in these same areas, has been shown to be activated in the brain 
by TAs, with evidence for this playing a role in the regulation of dopaminergic and 
psychostimulant action (Grandy, Miller & Li, 2016; Pei et al., 2016). TAAR1 was 
discovered near-simultaneously by two separate laboratories in 2001 (Borowsky et 
al., 2001; Bunzow et al., 2001), however research into its role in addiction has not 
progressed until recently owing to the development of antagonists and agonists that 
can be used to target this receptor (Lynch et al., 2013; Pei et al., 2016). TAAR1 acts 
as the mammalian receptor for trace amines in the CNS, having been identified in 
rodents and primates (Borowsky et al., 2001; Grandy et al., 2016). Due to its 
responsiveness to TAs and ease of identification in common mammalian model 
organisms such as rats and mice, TAAR1 is the most researched of the TAAR 
receptors (Liu & Li, 2018; Pei et al., 2016).  
TAAR1 regulation is complex, being activated not only by TAs but also by 
endogenous transmitters such as dopamine (DA) and serotonin (5-HT), and certain 
drugs of abuse such as methamphetamine (METH), MDMA, and LSD (Grandy et 
al., 2016; Pei et al., 2016; Pei et al., 2014). Due to its localisation within the CNS, 
TAAR1 is unique in that it is able to affect both DA and 5-HT neuronal firing 
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(Grandy et al., 2016), therefore making it an ideal candidate for designing 
pharmacological therapies for a range of neuropsychiatric disorders, including 
substance abuse.  
Research into the role of TAAR1 in addictive behaviours has already 
implicated its role in controlling the addictive effects of methamphetamine and 
cocaine. Administration of a selective partial TAAR1 agonist reduced cocaine-
induced locomotor hyperactivity and cocaine self-administration behaviour in mice 
(Revel, Mayer et al., 2012). Further studies conducted by Pei et al. (2014) showed 
that the administration of the partial TAAR1 agonists RO5203548 and RO5256390, 
prevented context-induced relapse to cocaine seeking after a two-week period of 
abstinence in rats, as well as drug-induced reinstatement of cocaine seeking. Another 
study conducted by Cotter et al., (2015) showed that treatment with the partial 
TAAR1 agonist, RO5203648, prevented the development of METH sensitisation in 
rats. In self-administration experiments, the partial TAAR1 agonist RO5263397 
reduced the break-point for METH in a progressive ratio schedule of reinforcement, 
suggesting that TAAR1 activation diminishes the motivation to self-administer 
METH (Pei et al., 2017). Following extinction training in the same rats, 
administration of the agonist blocked METH-primed reinstatement of METH 
seeking.  
Taken together, these findings showed that TAAR1 activation decreases the 
stimulant and reinforcing effects of psychostimulant drugs, effectively attenuating 
self-administration behaviour and relapse in rodent models (Pei et al., 2014; Pei et 
al., 2016). These effects have also been shown to be selective. Administration of 
TAAR1 agonists did not have any effect on the self-administration of natural 
rewards, such as sucrose, in control animals (Cotter et al., 2015; Pei et al., 2014). 
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These unique effects indicate that TAAR1 may be a modulator of the DA-mediated 
rewarding and reinforcing effects of addictive drugs (Lynch et al., 2013; Grandy et 
al., 2016). These reward mechanisms are also known to be involved in producing the 
same pattern of behaviour in relation to other drugs of abuse, including alcohol 
(Lynch et al., 2013). In the particular case of alcohol, this may occur through ethanol 
indirectly altering both DA transmission and TAAR1 signalling due to its ability to 
affect the levels of endogenous TAAR1 agonists (Lynch et al., 2013). Therefore, this 
evidence suggests that TAAR1 may be able to regulate alcohol-related behaviours 
(Lynch et al., 2013). 
Evidence suggesting an involvement of TAAR1 in alcohol-mediated 
behaviours is still scarce. A study conducted by Lynch et al. (2013) was the first to 
implicate the role of TAAR1 in the reinforcing effects of alcohol via affecting the 
reward pathways involved in addiction. In this study, both wild-type (WT) and gene 
knockout (KO) mice (mice who had undergone deletion of the TAAR1 gene) were 
given ethanol to drink in a two-bottle choice test. The KO mice drank significantly 
more alcohol than the WT mice. The sedative effects of alcohol, as measured by loss 
of righting reflex and locomotor tests were also stronger in KO mice, being more 
heavily affected at lower levels of concentration and for a longer duration, than WT 
mice. This showed that deletion of the TAAR1 gene in mice results in a stronger 
preference for ethanol and a greater sensitivity to its sedative effects when compared 
to controls. These results suggest that modulation of TAAR1 activity may be a novel 
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The Current Study 
There are currently no studies on the direct effects of TAAR1 activation with 
agonists on alcohol-related behaviours, which is the gap in the literature the current 
study aims to address. The aim of the current study is to therefore examine the 
potential therapeutic effects of TAAR1 activation on alcohol self-administration and 
sensitisation behaviours in a rodent model of alcohol addiction. To do this, mice will 
be trained to self-administer ethanol or sucrose over a period of five weeks using a 
two-bottle choice paradigm. Specific tests will be conducted to study the effects of 
TAAR1 activation on alcohol or sucrose consumption and preference. In these tests, 
mice will be administered with one of three treatments: saline 0.9% (control) or the 
TAAR1 agonist RO5263397 at either a low (3mg/kg) or high (10 mg/kg) dose. The 
two-bottle choice test has been widely used in animal studies of alcohol use as a 
measure of voluntary self-administration and preference for alcohol (Brabant et al., 
2014; Lynch et al., 2013).  
In addition, the current study will examine the acute locomotor response 
induced by alcohol and TAAR1’s ability to modulate such a response. To this effect, 
mice will undergo an open field locomotor assay. In this experiment, mice will be 
injected with one of four treatments (saline + saline [control], TAAR1 low dose + 
ethanol [low dose], TAAR1 high dose + ethanol [high dose], and saline + ethanol 
[ethanol]) and placed in an open field apparatus where distance travelled will be 
measured for 60 minutes. Locomotor behaviours due to drug sensitisation in rodent 
models are commonly assessed using an open field locomotor tests, with sensitised 
animals expected to show higher levels of activity on the relevant measurements 
(Brabant et al., 2014).  
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Mice have been chosen as the research subjects as animal models have been 
used extensively in alcohol research due to the resulting pharmacological and 
behavioural effects being similar to humans (Brabant, Guarnieri & Quertemont, 
2014). In the case of mammalian models based on rodents and primates, the 
underlying structure of the nervous system is also shared with humans, allowing the 
potential effects and behaviours presenting in humans to be more easily studied in 
these model systems (Brabant et al., 2014).  
The Swiss-Webster strain of mouse was chosen as they have been shown to 
respond to both alcohol self-administration and locomotor sensitisation challenges 
(Abrahao et al., 2013; Abrahao, Goeldner & Souza-Formigoni, 2014; Brabant et al., 
2014). Furthermore, only males were used due to the majority of studies in this area 


















Based on findings in previous studies, it is hypothesised that:  
1. TAAR1 activation will lead to significantly decreased ethanol intake (g/kg 
and mL) in a two-bottle choice paradigm. 
2. TAAR1 activation will lead to significantly decreased preference for ethanol 
compared to water (%) in a two-bottle choice paradigm. 
3. TAAR1 activation should not significantly change sucrose consumption 
(mL) and preference (%) in a two-bottle choice paradigm.  
4. TAAR1 activation will significantly reduce locomotor activity induced by an 





















38 male Swiss-Webster mice were used for the study. Power analyses for 
each experiment was conducted using estimations based on the standard deviation 
(SD) in previous experiments. This used the formula n = 1+2C(s/x) x 2, with C 
depending on significance level (0.05) and power (90%), s being the standard 
deviation of the measured variable, and x being the difference that was aimed to be 
detected in each experiment (National Research Council, 2003). Based on these 
calculations, and on previous research conducted in this field, a total of 9 units per 
experimental group (n = 9) was considered appropriate. In the self-administration 
experiments, the unit of research used was cage, as the mice were pair-housed, 
resulting in a minimum of 18 mice per experimental group (ethanol or sucrose). For 
the locomotor study, each mouse was tested singly, thus individual animals were the 
experimental unit, with a total of 38 animals divided between the four experimental 
groups (control group [n = 10], low dose group [n = 9], high dose group [n = 10], 
ethanol group [n = 9]). 
Animals were obtained from Australian Bio Resources and acclimated at the 
Medical Science Precinct (MSP) animal facility one week before the start of the 
study. Mice were pair-housed in standard mouse cages and were maintained at 
temperatures of 22°C ± 2, with a 12:12 hour day-night cycle (lights on at 7:00 am). 
Enrichment was provided in each cage to reduce the effects of impoverished 
housing, and animals had ad libitum access to food. Animals were monitored daily 
for signs of injury or sickness by the student (monitoring sheets located in Appendix 
2 and 3). All housing and procedures were carried out with the ethical approval of 
the University of Tasmania Animal Ethics Committee (A0018015, Appendix A).  





For the self-administration test solutions of ethanol and sucrose were made 
by mixing pure (100%) undenatured ethyl alcohol (Sigma Aldrich) and/or white 
sugar (CSR) with acidified water. Three ethanol solutions at concentrations of 3% 
ethanol and 3% sucrose, 6% ethanol and 1% sucrose, and 10% ethanol were made 
for the ethanol group. Three solutions of 3% sucrose, 6% sucrose and 10% sucrose 
were made for the sucrose group. Solutions were administered via non-spilling water 
bottles during the training and testing phase.  
 
Open field apparatus 
The open-field apparatus was constructed out of Perspex (0.3 x 0.3 x 0.3m). 
Ethovision XT video tracking software was used to record the distance travelled by 
mice inside the open field.  
 
Pharmacological treatments 
A 20% vv ethanol solution was made by mixing pure (100%) undenatured 
ethyl alcohol (Sigma Aldrich) with sterile 0.9% sodium chloride (Livingston 
International). 20% ethanol was injected at a volume calculated using the formula: 2 
x (animal weight/160), resulting in a 2g/Kg dose. 
TAAR 1 agonist RO5263397 was obtained in powdered form from 
Hofmann-La Roche Ltd (Switzerland) through a Materials Transfer Agreement and 
diluted with sterile 0.9% sodium chloride (Livingston International) at 
concentrations of 0.6 and 2 mg/mL and administered at doses of 3 and 10 mg/kg.   
 




Experiment 1: Ethanol and Sucrose Self-Administration 
Mice were exposed to a two-bottle choice paradigm in order to assess the 
effects of TAAR1 on ethanol self-administration. Cages were assigned to one of two 
groups, one receiving ethanol and the other receiving sucrose, resulting in a total of 
10 cages per group. Two mice from the sucrose group were culled due to injuries 
resulting from fighting before the first self-administration test, reducing the number 
of mice in the sucrose group to 18 (n = 18). Cages in both groups were equipped 
with two non-spilling drinking bottles, one containing water and the other containing 
either an ethanol or sucrose solution depending on their group allocation. 
 
Continuous Training Phase 
Mice first underwent training in order to teach them to consume their 
treatment solutions reliably. During this phase, animals had ad libitum access to both 
one water and one treatment bottle on weekdays, and two water bottles only on 
weekends for a 3-week period. Bottles were weighed daily by the student to measure 
consumption (mL), and replenished with fresh solution, before the position of the 
bottles in the cage being swapped (front or back) to control for side biases. Figure 1 
shows a diagrammatic representation of the continuous training phase.   
Ethanol Group 
For the ethanol group, the concentrations of ethanol in the treatment were 
gradually increased over the course of three weeks in order to acclimate the animals 
to the taste and strength of the ethanol. These concentrations were 3%, 6%, and 10%. 
Each concentration was given over the course of 5 days. To facilitate the drinking of 
ethanol, a sucrose fading procedure was also implemented for this group. This is a 
EFFECTS OF TAAR1 ACTIVATION ON ALCOHOL ABUSE 
	
22	
common and established technique used to initiate ethanol self-administration in 
two-bottle preference tests in rodent models (Carrillo et al., 2008; Cotter et al., 2015; 
Samson, Tolliver, Pfeffer, Sadeghi & Haraguchi, 1988; Tolliver, Sadeghi & Samson, 
1988). This procedure involved sweetening the ethanol by adding sucrose in order to 
make it more palatable to the animals, and then fading this out over the course of two 
weeks. The concentrations used for this were 3% sucrose for the first week and 1% 
for the second week. This resulted in the final solutions administered to animals in 
the ethanol group being 3% ethanol and 3% sucrose in week 1, 6% ethanol and 1% 
sucrose in week 2, and 10% ethanol in week 3.  
Sucrose Group 
For the sucrose group, the concentrations of sucrose in the treatment were 
gradually increased over the course of three weeks in order to acclimate the animals 
to the taste and strength of the sucrose. These concentrations were 3%, 6%, and 
10%. Each concentration was offered over the course of 5 days.  
 
Figure 1. Diagrammatical representation of the continuous training phase 
 
Intermittent training phase 
After conclusion of the third week of continuous drinking, animals were then placed 
on an intermittent exposure schedule for a period of two weeks. This was done to 
further facilitate drinking of ethanol in the mice (Rosenwasser, Fixaris, Crabbe, 
Brooks & Ascheid, 2013). Previous studies on alcohol self-administration have 
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successfully used this method to increase alcohol intake in rodent models 
(Rossenwasser et al., 2013; Warden et al., 2019). During this phase, animals had 
access to both one water and one treatment bottle on every second weekday 
(Mondays, Wednesdays, and Fridays), and access to two water bottles only on 
remaining weekdays (Tuesdays and Thursdays) and weekends. Please refer to Table 
1 for a diagrammatic representation of the intermittent training schedule.  
 
Table 1 
Schedule of intermittent exposure. All treatments are at 10% concentration 
Week 1 Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Bottle 1 Treatment Water Water Water Treatment Water Water 
Bottle 2 Water Water Treatment Water Water Water Water 
Week 2 Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Bottle 1 Treatment Water Water Water Treatment Water Water 
Bottle 2 Water Water Treatment Water Water Water Water 
 
Testing Phase 
For the testing phase of this experiment, cages from each group (ethanol or 
sucrose) were randomly assigned to one of three treatment presentation orders using 
a Latin Square design, as shown in Table 2. The protocol determined the order each 
animal underwent exposure to the three pharmacological treatments (saline as 
control, TAAR1 agonist low dose and TAAR1 agonist high dose) in this repeated 
measures design. The treatments used were 0.9% sodium chloride (control), 3mg/kg 
of TAAR1 agonist (low dose) and 10mg/kg of TAAR1 agonist (high dose). The 
agents were administered via intraperitoneal (i.p.) injection, at a volume of 5 mL/kg 
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of body weight. On the day of testing, animals were deprived of all liquids for four 
hours in the morning in order to facilitate drinking in the two-bottle choice testing 
period. After this four-hour period, mice were briefly removed from their home 
cages to be administered their treatment (saline, TAAR1 agonist low dose or TAAR1 
agonist high dose). Mice were then returned to their home cage, which was fitted 
with two bottles: one containing water and the other containing their treatment (10% 
sucrose or 10% ethanol). Mice had access to the bottles for four hours. Bottles were 
weighed before the test, at one-hour intervals during the testing period, and at 
completion of the testing session to determine the amount of liquid consumed (mL 
and g/kg of body weight). This was done in order to track drinking patterns over the 
four hours as the effects of the TAAR1 agonist could begin to wear off after the first 
hour. After completion of the test session, mice were returned to their intermittent 
exposure schedule for the rest of the week. This testing procedure was repeated for a 
total of three times to ensure each cage received all three treatments, with a one-
week stabilisation period between each session. Figure 2 shows a diagrammatic 
representation of this paradigm.   
At completion of the final self-administration testing session, animals no 
longer had access to ethanol or sucrose. During the next 14 days mice had ad libitum 











Latin-square design for the two-bottle choice paradigm testing order 
  Ethanol Group Sucrose Group 
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Figure 2. Diagrammatic representation of the two-bottle choice paradigm 
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Experiment 2: Measuring Ethanol-Induced Locomotor Activity 
Mice were semi-randomly assigned to one of four treatment groups: Control 
(0.9% saline + 0.9% saline), Ethanol (0.9% saline + 20% ethanol), TAAR1 low dose 
(3 mg/kg of RO5263397 + 20% ethanol) and TAAR1 high dose (10 mg/kg of 
RO5263397 + 20% ethanol), with group allocation from the previous self-
administration test (ethanol or sucrose) counterbalanced across the four treatment 
groups. There was a total of nine mice per group (n = 9). The mice were injected i.p. 
with the first agent depending on their group allocation: 0.9% saline (control) and 
either a low or high dose of the TAAR1 agonist RO5263397. Mice were then placed 
in the open-field for a 10-minute habituation period, and then injected with the 
second agent (0.9% saline or 20% ethanol) and placed in the open field for a 60-
minute locomotor recording session. Total distance travelled in the hour (cm) was 
measured. Saline and TAAR1 agonist were injected at a volume of 5ml/kg, and 20% 
ethanol was injected at a volume calculated using the formula: 2 x (animal 
weight/160). Figure 3 shows a diagrammatic representation of the locomotor testing 
procedure. Figure 4 shows how the locomotor fields were arranged and recorded. 
 
 
Figure 3. Locomotor assay experimental procedure 
 
 




Figure 4. Open field locomotor assay arrangement. Four mice were tracked at a time 
using Ethovision XT.  
 
Design 
The self-administration experiment utilised a counterbalanced within-
subjects Latin Square design. Independent variables were treatment (ethanol/sucrose) 
and dose (saline 0.9%, TAAR1 agonist 3mg/kg, TAAR1 agonist 10 mg/kg). 
Dependent variables were amount of liquid consumed (g/kg and mL for ethanol; mL 
only for sucrose) and preference (%). 
The locomotor assay experiment utilised a mixed within/between-subjects 
design. Animals were semi-randomly assigned to treatment groups to ensure even 
distribution of ethanol- and sucrose-exposed animals across the groups. The 
independent variable was treatment (control [saline 0.9% + saline 0.9%], ethanol 
EFFECTS OF TAAR1 ACTIVATION ON ALCOHOL ABUSE 
	
28	
[saline 0.9% + ethanol 20%], low dose [TAAR1 low dose + ethanol 20%], high dose 
[TAAR1 high dose + ethanol 20%]). The dependent variable was distance moved in 
60 minutes (cm), measured in 10-minute time bins. 
 
Data Analysis 
Statistical analyses were conducted in Jamovi (v.1.1.30) and StatView 5.0. 
Prior to ANOVAs, all data was assessed for normality of distribution, independence 
of subjects, sphericity, and was also assessed for outliers. For the self-administration 
paradigm, repeated measures ANOVAs were conducted for consumption and 
preference of treatment solutions in the continuous training phase, testing weeks and 
the self-administration test itself. Significant differences and interactions were 
further assessed using Tukey’s post hoc tests, and estimated marginal means using 
the standard error of the mean were plotted. 
For the locomotor assay, a mixed ANOVA with treatment as the between-
subjects factor was conducted. Distance travelled over a 60-minute period (cm) was 
measured in 10-minute time bins for each animal. Two animals were excluded from 
the locomotor analysis as they exhibited stress reactions prior to, and within the test 
itself. One-way ANOVAs were conducted to measure distance travelled in the 10-
minute habituation period before the test and the total distance travelled in the test 
itself. Significant effects and interactions were further assessed using Tukey’s post 
hoc tests. Estimated marginal means using the standard error of the mean were 
plotted.  
For all analyses, alpha level was set at 0.05. 
 
 




Experiment 1: Self-Administration Two-Bottle Choice Paradigm 
Training Phase: Continuous Exposure Ethanol Group 
Repeated measures ANOVAs showed a significant difference in treatment 
concentrations for ethanol consumption in both g/kg F(2, 18) = 6.02, p = .010, η²p = 
.401, and mL F(1.18, 10.6) = 69.5, p<.001, η²p = .88 after a Greenhouse-Geisser 
correction, and ethanol preference F(1.12, 10.1) = 38.4, p<.001, η²p = .81.  
For consumption in g/kg, Tukey’s post-hoc tests showed that consumption at 
3% was significantly lower than consumption at 6% p = .008. For consumption in 
mL, Tukey’s post-hoc tests showed a significant difference p<.001, between all three 
concentrations, with consumption being highest at 3% and decreasing gradually at 
6% and 10%, indicating that animals drank less as the concentration of ethanol 
increased (and the sucrose concentration decreased). For ethanol preference, Tukey’s 
post-hoc tests showed a significant difference between 3% and 10% p<.001, and 6% 
and 10%, p<.001. Preference for ethanol solution in comparison to water was highest 
at 3% and lowest at 10%, indicating that preference for the ethanol solution 
decreased as the ethanol concentration increased (and the sucrose levels decreased), 
which was expected. 
 
Training Phase: Continuous Exposure Sucrose Group 
Repeated measures ANOVAs found a significant difference between sucrose 
concentration in terms of sucrose consumed (mL) F(2, 18) = 4.99, p = .019, η²p = 
.36, and sucrose preference (%) F(2, 18) = 16.1, p<.001, η²p = .64.  
Tukey’s post-hoc tests found a significant difference in terms of sucrose 
consumed at 3% and 6% p = .039, and 3% and 10% p = .031, with consumption 
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showing a gradual increase across concentrations, being lowest at 3% and highest at 
10%. Therefore, as sucrose concentration increased, sucrose consumption also 
increased, which was expected. A similar pattern was found for sucrose preference, 
with Tukey’s post-hoc tests revealing a significant difference between preference at 
3% and 6% p = .007, and 3% and 10% p<.001. As expected, preference for sucrose 
over water gradually increased over the concentrations, being lowest at 3% and 
highest at 10%. 
 
Training Phase: Intermittent Exposure Ethanol Group 
Repeated measures ANOVAs showed no significant difference between 
continuous and intermittent exposure in terms of ethanol consumption (in both g/kg 
and mL) and preference, indicating that intermittent exposure did not have the 
intended effect of increasing ethanol intake. 
 
Sucrose Group Training Phase: Intermittent Exposure 
Repeated measures ANOVAs showed no significant difference between 
continuous and intermittent exposure in terms of sucrose consumption (mL) and 
preference. Both sucrose consumption and preference for sucrose increased in the 
intermittent exposure period, compared to the continuous period, however, as 
previously shown for ethanol, intermittent exposure did not significantly increase 
consumption. 
 
Ethanol Group: Two-Bottle Choice Test 
A repeated measures ANOVA showed a significant difference between 
treatment doses F(2, 18) = 6.09, p = .010, η²p = .40, and a significant interaction 
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between treatment dose and hour F(6, 54) = 2.31, p = .047, η²p = .204 in terms of 
ethanol consumption (g/kg). Tukey’s post hoc tests showed a significant difference 
between saline and TAAR1 agonist low dose p = .018, and TAAR1 agonist high 
dose p = .021, with saline-treated animals drinking significantly more ethanol than 
mice treated with the TAAR1 agonist.  
Tukey’s post-hoc tests showed a significant difference between saline in the 
first hour, and TAAR1 agonist low dose in the first hour p = .019, second hour p = 
.002, third hour p = .002, and TAAR1 agonist high dose in the first hour p = .005, 
second hour p = .010, third hour p = .032, and fourth hour p = .005, saline in the 
third hour p = .035, and fourth hour p = .040. Saline-treated animals drank 
significantly more ethanol (g/kg) in the first hour than any other group, before 
decreasing steadily over time. During the second, third and fourth hours, all three 
groups were drinking ethanol at similar levels (g/kg) (Figure 5).  
Repeated measures ANOVAs showed no significant differences or 
interactions for ethanol consumption (mL) and ethanol preference (%), but did show 
a significant difference for the factor, hour F(3, 27) = 4.81, p = .008, η²p = .35, and a 
significant interaction of dose*hour F(6, 54) = 3.38, p = .007, η²p = .27 for water 
consumption (mL). Tukey’s post-hoc tests showed saline-treated animals consumed 
significantly more water in the first hour than in the second p = .006 and fourth 
hours p<.001, low dose TAAR1 agonist animals in the second p = .014, third p = 
.012, and fourth hours p = ,014, and high dose TAAR1 agonist animals in the first p 
= .021 and second hour p = .003. Water consumption (mL) for the saline group 
generally decreased over time, as consumption in the second, third and fourth hours 
was on a similar level to the agonist-treated groups, which generally drank less 
(Figure 6). 




Figure 5. Ethanol consumption (g/kg) in the two-bottle choice test. Error bars are 



































Figure 6. Water consumption (mL) in the ethanol group in a two-bottle choice test. 
Error bars are SEM. 
 
Sucrose Group: Two-Bottle Choice Test 
A repeated measures ANOVA found a significant difference between 
treatment doses F(2, 18) = 4.95, p = .019, η²p = .35, and a significant interaction 
between treatment dose and hour F(6, 54) = 2,96, p = .014, η²p = .25 in terms of 
sucrose consumed (mL).  
Tukey’s post-hoc tests showed a significant difference between saline and the 
high dose of the TAAR1 agonist p = .025, with saline-treated animals drinking 
significantly more sucrose (mL) than high dose agonist-treated animals in the test 
overall.  
Tukey’s post-hoc tests also showed a significant difference between saline in 
the first hour and second hours p = .034, TAAR1 agonist low dose in the first hour p 
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in the first hour p = .002 and second hour p<.001. Saline-treated animals drank 
significantly more sucrose (mL) than mice treated with the TAAR1 agonist in the 
first hour, before showing a significant decrease in the second hour, with a gradual 
increase in the last two hours of the test. Saline-treated animals always drank more 
than animals treated with the TAAR1 agonist across the entire test (Figure 7). 
For sucrose preference (%) and water consumption (mL), repeated measures 
ANOVAs found no significant differences or interactions. 
 
Figure 7. Sucrose consumption (mL) in the two-bottle choice test. Error bars are 
SEM. 
 
Experiment 2: Open-Field Locomotor Assay 
A between-subjects ANOVA found no significant differences between 
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period. However, agonist-treated animals showed lower levels of activity than both 
saline- and ethanol-treated animals. 
 
A mixed ANOVA with treatment as a between-subjects factor showed a 
significant difference between the time bins F(2.49, 77.1) = 11.5, p<.001, η²p = .27 
after a Greenhouse-Geisser correction, and treatment F(3, 31) = 7.89, p<.001, η² = 
.25 in terms of distance travelled (cm). No significant interactions were found. 
Tukey’s post-hoc comparisons for the factor, time, found a significant 
difference between the first 10 minutes of the test, and the 10-20 minute bin p = 
.007, 20-30 minute bin p<.001, 20-30 minute bin p<.001, 30-40 minute bin p<.001, 
40-50 minute bin p<.001, and 50-60 minute bin p<.001. This showed that activity for 
all groups was highest in the first 10 minutes of the test, before decreasing as the test 
progressed.  
 Tukey’s post-hoc comparisons for treatment found a significant difference 
between ethanol-treated animals and animals exposed to the TAAR1 agonists p = 
.002, with TAAR1 treatments being able to attenuate ethanol-stimulated locomotor 
activity across the entire test (Figure 8). 
 




Figure 8. Distance travelled (cm) over 60 minutes in an open-field locomotor assay. 
Error bars are SEM. 
 
For total distance travelled (cm) in the test, a between-subjects ANOVA 
found a significant difference between treatments F(3, 31) = 7.89, p<.001, η² = .43. 
Tukey’s post-hoc tests showed that overall, ethanol-treated animals travelled a 



































The current study aimed to determine the potential therapeutic effects of 
TAAR1 activation on a range of alcohol addiction behaviours by using a rodent 
model of chronic alcohol drinking. Animals underwent a two-bottle choice paradigm 
to assess alcohol self-administration and preference behaviours, and an open-field 
locomotor assay to evaluate locomotor activity induced by an acute alcohol 
challenge.  
The results of the self-administration experiment showed that, as predicted, 
administration of the TAAR1 agonist, RO5263397, significantly decreased ethanol 
consumption in g/kg in the first hour of the preference test. However, RO5263397 
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which was unexpected, suggesting that, at the doses tested, RO5263397 induced 
non-specific effects. Furthermore, TAAR1 activation appeared to have no effect on 
ethanol consumption in mL or affect preference for either ethanol or sucrose.  
The results of the locomotor sensitization experiment showed that 
RO5263397 decreased locomotor activity evoked by alcohol treatment, which was 
expected. There were also no significant differences between the control and ethanol 
groups except in the first 10 minutes of the test, which was unexpected as ethanol-
treated animals were expected to show a significantly higher level of activity than 
control animals. Furthermore, the significantly reduced locomotion in TAAR1-
activated groups compared to both saline and ethanol groups may be due to non-
specific effects of the TAAR1 agonist.   
 
Self-Administration Training Phase 
The results of the continuous training phase for self-administration were as 
predicted. Animals in the ethanol group increased their consumption and preference 
for ethanol when they were transferred from 3% to 6% alcohol, before decreasing at 
10%, which was expected due to the removal of sucrose at this concentration. The 
sucrose group showed a significant increase in consumption and preference for 
sucrose as concentration increased, which was expected as mice find sucrose 
solutions highly palatable (Carillo et al., 2008).  
Contrary to our prediction, the intermittent exposure period did not 
significantly increase consumption in either group, with the ethanol group showing a 
slight decrease at the end of the intermittent training phase in comparison to the end 
of the continuous training phase, while the sucrose group showed a slight increase. 
Despite this, animals were still readily consuming their solutions at levels suitable 
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for conducting the two-bottle preference test. Furthermore, as the animals were 
drinking for a period of 5 weeks, mice could be said to have engaged in chronic 
alcohol drinking before the two-bottle preference tests commenced. 
 
Two-Bottle Choice Paradigm 
The prediction that RO5263397 administration would significantly reduce 
alcohol intake in the first hour compared to control treatment was supported in the 
consumption (g/kg) analysis. Animals treated with the agonist did not increase their 
general intake over the course of the test, with saline-treated animals significantly 
decreasing in intake after the first hour to be on par with TAAR1-treated animals. 
Interestingly, there also seemed to be no difference in effectiveness between 
the low and high doses of TAAR1 agonist; both doses significantly reduced drinking 
in the first hour, with animals treated with the low dose drinking slightly more than 
those treated with the high dose, though this difference was not significant. This 
could suggest that the effectiveness of TAAR1 activation on alcohol self-
administration behaviour does not depend on dose, which contrasts with studies on 
METH and cocaine self-administration using self-administration protocols in rats. 
These studies showed changes in the rate of self-administration was dose-dependent, 
with higher doses of TAAR1 agonist resulting in lower rates of self-administration 
(Cotter et al., 2015; Pei et al., 2014; Revel et al., 2012).  
Moreover, animals treated with the TAAR1 agonist did not show a rebound 
increase in consumption at any point, which may imply that TAAR1 activation could 
be effective in preventing a return to drinking. This could show that treatment with 
the TAAR1 agonist may reduce the motivation to consume ethanol, which may also 
support the hypothesis that TAAR1 activation could be beneficial in treating 
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withdrawal symptoms (Grandy et al., 2016; Lin & Li, 2018; Lynch et al., 2013; Pei 
et al., 2016). This behaviour was also seen in previous studies conducted on cocaine-
addicted animals, where administration of the agonist also prevented a return to 
drug-seeking in rats (Pei et al., 2014). However, further study on this particular 
effect is warranted before drawing firm conclusions.  
 
However, the prediction of RO5263397 significantly reducing ethanol 
consumption was unsupported by the consumption (mL) results. The pattern of 
consumption was less clear in the mL analysis, which showed no significant effects 
or interactions after a Greenhouse-Geisser correction, although the effect size for the 
hour*dose interaction was moderate and similar in size to the g/kg interaction. 
Animals exposed to the TAAR1 agonist were shown to drink less than saline 
controls, but this was only a small difference and was not shown to be significant. 
Furthermore, animals treated with TAAR1 at the lowest dose also showed a large 
increase in consumption in the final hour of the test, showing a difference between 
the two doses in terms of effects. This also contrasts with the results of the g/kg 
analysis.  
 This could possibly be due to the dose being too low to fully prevent a return 
to drinking, which was not seen in the high dose animals. Previous studies on 
cocaine and METH self-administration in rats have shown that higher doses of 
TAAR1 agonists mitigate relapse to drug-seeking, whereas lower doses are less 
successful at this (Pei et al., 2014; Pei, Asif-Malik, Hoener & Canales, 2016; Thorn 
et al., 2014), a finding which appears to be mirrored here. It also makes the 
conclusion that TAAR1 activation suppresses alcohol withdrawal symptoms less 
supported at lower doses of the agonist. The seemingly inconsistent pattern with the 
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g/kg consumption results could also be explained by the amount consumed only 
increasing slightly by approximately 0.17 mL, which may not be enough to cause a 
sizeable change in g/kg consumed but was enough to be significantly different in 
terms of mL consumed. It is also important to note that the g/kg measurements take 
into account the weight of the animal and therefore provide a more reliable estimate 
of alcohol consumption and its associated psychopharmacological effects. 
 
The prediction involving ethanol preference was also unsupported by the 
results. None of the treatment groups were significantly different to each other in 
terms of preference, with the high dose agonist animals actually showing the most 
preference for ethanol in the first hour at approximately 48%, compared to the saline 
and low dose TAAR1 animals which were at approximately 40%. However, the high 
dose group did decrease in preference over the four hours, becoming the lowest 
group in the fourth hour while the control and low dose groups gradually increased. 
Again, this contrasts with previous findings by Lynch et al. (2013) which showed 
that TAAR1 knockout mice have a significantly higher preference for ethanol in a 
two-bottle choice test than wild-type, implicating a role of TAAR1 in controlling this 
variable. 
 
Finally, the prediction that sucrose consumption would be unaffected by 
TAAR1 activation was unsupported, which is a major difference to previous studies 
showing that TAAR1 activation has substance-specific effects (Cotter et al., 2015; 
Pei et al., 2014; Revel et al., 2012). The results of the sucrose consumption (mL) 
analysis showed that animals treated with the TAAR1 agonist consumed 
significantly less sucrose (mL) than saline animals in the first hour of the test, 
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mirroring the results from the ethanol group (g/kg). It appears that the control 
animals displayed a sharp spike in consumption of sucrose in the first hour of the 
test, which is not surprising given their liquid deprivation immediately prior to the 
test commencing. This rate of consumption quickly fell by the second hour after 
satiation occurred. The significant difference in consumption between the TAAR1 
agonist groups (high and low dose) and control group in the first hour is indicative 
that the TAAR1 agonist is inhibiting the initial spike in consumption that 
immediately follows liquid deprivation, as seen in the saline group.  Therefore, these 
results show that TAAR1 agonists seem to also have non-specific effects on 
treatment consumption.  
Our prediction in terms of sucrose preference was supported, with no 
significant differences or interactions found. High dose agonist-treated animals did 
show less of a preference for sucrose compared to saline and low dose agonist-
treated animals, with this increase after the first hour to be approximately the same 
as the latter two groups by the third hour.  
 
In summary, the results of the two-bottle choice paradigm only supported 
two of our predictions: administration of a TAAR1 agonist did cause a significant 
decrease in ethanol consumption (g/kg), and sucrose preference was not affected by 
administration of the same agonist. RO5263397 did not cause a significant decrease 
in ethanol consumption (mL) or preference, while producing an unexpected effect by 
significantly reducing sucrose and water consumption (mL). Therefore, the effects of 
TAAR1 activation in the current study were not drug-specific.  
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Based on these results, it is possible that the discrepancies between findings 
in previous studies and the behavioural results in the present study could be due to 
the comparatively higher doses of the TAAR1 agonist, as well as species differences 
(Pei et al., 2017; Thorn et al., 2014). Such dosage, combined with the higher 
sensitivity of mice to TAAR1 activation, compared to rats, may have reduced motor 
activity overall in the current experiments (lethargy, impaired motor ability, etc.). 
This may be supported by the results of the sucrose consumption analysis (mL) and 
water consumption (mL) analysis in the ethanol group, as both were also shown to 
be significantly lower in animals exposed to RO5263397 in the first hour. This was 
unexpected as the effects of TAAR1 activation should be specific to ethanol 
consumption only. However, if activity was suppressed by the TAAR1 agonist, then 
this decrease in sucrose and water consumption would also make sense as animals 
would be less active overall.  
 
Locomotor Sensitisation Test 
Our prediction was not fully supported by the results of the open field 
locomotor activity test. In the first 10 minutes of the test, ethanol-treated animals 
showed a significantly higher level of activity than the saline and TAAR1-treated 
animals, which was expected. Furthermore, the activity levels of both saline and 
agonist animals were approximately the same, seemingly showing that TAAR1 
activation blocked the effects of acute ethanol sensitisation on locomotor activity, 
resulting in a similar activity profile to non-ethanol animals. However, for the 
remainder of the 60-minute test, ethanol animals decreased in activity to be on par 
with saline animals. This contrasts with our expectations that acute ethanol-
challenged animals would show a significantly higher level of activity compared to 
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saline controls, therefore exhibiting acute locomotor sensitisation. Therefore, we 
cannot say that acute locomotor sensitisation occurred in our experiment. Another 
unexpected result was that agonist-treated animals at both doses showed 
significantly lower activity than both ethanol- and saline-treated animals. While this 
did support our prediction that agonist-treated animals would show less activity than 
ethanol-treated animals, this did not fully support our other prediction that their 
activity level would be comparable to saline control animals, as it was significantly 
depressed compared to this group. Interestingly, like the results of the ethanol 
consumption (g/kg) analysis in the two-bottle choice test, effects on locomotor 
activity were not dose dependent. Furthermore, these results also seem to support the 
hypothesis that the non-specific effects of TAAR1 agonist treatment, at least within 
the dose range used in this study, may suppress locomotor activity overall.  
 
 
In conclusion, most of our predictions were not fully supported by the results 
of the current study. While TAAR1 activation did produce a significant reduction in 
ethanol consumption (g/kg) in a model of chronic alcohol abuse, the same effects 
were not found for ethanol preference or consumption in mL. Furthermore, these 
effects were also found in controls, such as water and sucrose consumption, which 
was unexpected as previous studies have shown that the effects of TAAR1 activation 
were selective and specific to drugs of abuse (Cotter et al., 2015; Pei et al., 2014; 
Revel et al., 2012; Thorn et al., 2014).  
It is possible that TAAR1 activation through partial agonists can result in 
other non-specific effects that may cause an overall reduction in activity, which 
would affect both drinking behaviours and locomotor activity regardless of 
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treatments or substances consumed (Pei et al., 2017; Thorn et al., 2014). The results 
of the locomotor test also seemed to support this hypothesis, as activity in agonist-
treated animals was significantly depressed and not dose-dependent across the 
majority of the test when compared to saline-control animals. This was unexpected, 
as results from previous studies show that agonist-treated animals should display 
similar levels of activity to control animals, with activity lessening as dose increases 
(Thorn et al., 2014). Furthermore, as ethanol-treated animals did not show a 
significantly higher level of activity than saline animals throughout the test, we also 
cannot conclude that the animals experienced acute locomotor sensitisation. 
 
Possible reasons behind the extent of the non-specific effects observed in this 
study could be due to the doses used being based on rat studies, which are known not 
to produce non-specific effects on locomotor activity (Thorn et al., 2014). Despite 
the similarity between the species, mice have not been used as models in many 
studies that involve the use of TAAR1 agonists. It is possible that the doses used in 
the study were either too large for mice, or that mice are possibly more sensitive to 
the effects of TAAR1 agonists than rats, resulting in an overall depression in 
activity. Previous studies in rats have reported some mild non-specific effects at high 
doses of TAAR1 agonists (eg. 10mg/kg), including distractibility and slowness of 
movement during behavioural tests (Pei et al., 2017; Thorn et al., 2014), which may 
further support this conclusion. However, evidence in the literature for these non-
specific effects is limited, thereby warranting more research in this area. 
 
Regarding the results of the two-bottle choice test, it is also possible the 
training phase may have been too short to produce a reliable rate of chronic ethanol 
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intake. Previous studies utilising the same procedure often train mice to consume 
their treatment at longer intervals and higher strengths until a reliable baseline level 
of drinking is reached, especially if they are not of an alcohol-preferring strain 
(Abrahao et al., 2013; Becker & Lopez, 2004; Lynch et al., 2013). For example, 
Lynch et al. (2013) had mice trained to consume ethanol for 10 weeks, at a higher 
number of concentrations, which ensured a higher and more reliable rate of chronic 
drinking. While extending the training phase until a reliable baseline level of 
consumption had been established was originally planned for this study, this was 
unable to be implemented due to time constraints. Therefore, it is possible that the 
mice in the current study simply did not have enough time to become reliably 
accustomed to drinking ethanol, which may have affected results.  
This may also account for the lack of locomotor sensitisation due to acute 
ethanol challenge in the locomotor test. Previous studies on ethanol-induced 
behavioural sensitisation in Swiss-Webster mice do show that the development of 
this effect often depends on individual differences, with individual preference for 
ethanol being one of the factors that account for the most variability (Abrahao et al., 
2013). Non-sensitised animals in this study showed similar levels of locomotor 
activity to saline control mice after an acute ethanol challenge, which are results 
mirrored in the current study. Therefore, it is possible that not enough of the animals 
in the experiment were sensitised to the effects of ethanol prior to the experiment.  
 
In summary, the current study was inconclusive on the possible therapeutic 
effects of TAAR1 activation in a rodent model of chronic alcohol abuse. While 
TAAR1 activation did cause a significant reduction in ethanol consumption in g/kg, 
no effects were found on ethanol consumption in mL or ethanol preference which 
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contradicted our hypotheses. Furthermore, sucrose and water consumption (mL) was 
also found to be significantly reduced by TAAR1 activation, which contradicted 
previous findings and questioned the specificity of the findings. Our hypotheses for 
locomotor sensitisation due to ethanol were also unsupported as ethanol-treated 
animals did not show acute locomotor sensitisation behaviours in the majority of the 
test. While TAAR1-treated animals did show significantly less activity than ethanol 
animals, they were also significantly lower than control animals, which was 
unexpected.   
Possible follow-ups to this study should consider the use of adjusted doses, 
such as 0.3 mg/kg and 1 mg/kg, or the use of rats as a model instead of mice, as most 
research on TAAR1 activation with agonists have been done on rat models. 
Replications of this study should also consider the use of an extended training phase 
and assessment of baseline drinking preceding the two-bottle choice paradigm in 
order to increase the reliability of chronic drinking in the rodent model.  
A follow-up to the current study would be especially helpful as this is 
currently one of very few studies on the effects of TAAR1 on alcohol addiction 
behaviours and it is the only one thus far to investigate the direct effects of TAAR1 
activation with an agonist. Most of the findings of the current study also contradict 
previous findings in other drug addiction models, therefore further clarification of 
these results would be especially helpful. There is also a need for more research on 
the potential therapeutic effects of TAAR1 on a range of alcohol addiction 
behaviours is especially warranted, as this area of study is still relatively unknown 
and has a great number of potential benefits for clinicians and patients of an AUD. 
The results of this study also warrant further investigation into the possible 
non-specific effects of TAAR1 activation with agonists in rodent models and 
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humans, as this may have a multitude of implications for the development of 
pharmacological treatments that aim to utilise this receptor as a target. More 
knowledge of these potential effects, especially in humans, is needed before 
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(Normal = 0; hunched = 2; trembling=3) 
Movement/Gait  (Normal=0; slight weakness or incoordination=1; 
reluctance to move or marked weakness or marked 
incoordination=2; staggering/limb 
dragging/paralysis=3) 
Coat condition  (Normal/groomed=0; rough=1; ruffled/unkempt=2; 
bleeding or infected wounds or self mutilation=3) 
Eating/drinking  (normal=0; decreased intake during the 1st 24 hrs 
day=1; decreased intake more than 1 day=2; 
decreased intake over 48hrs=3) 
Breathing  (normal=0; rapid, shallow=1; rapid, abdominal 
breathing=2; laboured, 
irregular ,extremities/membranes grey/blue=3) 
ON HANDLING  
Alertness (normal=0; dull or depressed=1; little response to 
handling=2; unconscious or aggressive=3) 
Body weight (gm or kg / 
Score)  
 
(normal weight & growth rate=0; reduced growth 
weight=1; chronic weight loss>15% =2; weight loss = 
or >20%=3) 
Dehydration  (none=0; skin less elastic=1; skin tenting=2; skin 
tenting & sunken eyes=3) 
Eyes, Nose  (normal=0; wetness or dull eyes=1; discharge/squinty 
eyes=2; coagulated nasal discharge/matted eyes=3) 
Faeces  (normal=0; moist but formed=1; loose, soiled peri-
anal area or mucoid=2; watery or no faeces for 48hrs 
or blood=3) 
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o A	total	score	of	6	or	higher	across	all	parameters.	
	
• Criteria	for	immediate	veterinary	treatment	required:			
o Assessment	score	of	2	for	any	of	the	following	clinical	observations:	Activity,	
Movement/Gait,	Breathing,	Alertness,	or	Body	weight	loss	is	equal	to	or	greater	
than	10%.	
OR	
o A	total	score	of	4	or	higher	across	all	parameters.	
	
• Criteria	for	increased	monitoring	to	twice	daily:	
o A	total	score	of	1-3	across	all	parameters.	
 
	
		
 
 
 
 
 
